CCDC113: A Potential Drug Target and Biomarker for Inflammatory and Neoplasmic Diseases

Target Name: CCDC113

NCBI ID: G29070

CCDC113

CCDC113: A Potential Drug Target and Biomarker for Inflammatory and Neoplasmic Diseases

CDC113 is a protein that is expressed in various tissues and cell types in the human body. Its function is not well understood, but it is known to be involved in the regulation of cell growth, differentiation, and inflammation. The protein is localized to the endoplasmic reticulum and is predominantly expressed in the liver, spleen, and skeletal muscle.

CDC113 is a member of the CDC family, which includes several structurally similar proteins that are involved in the regulation of various cellular processes. The most well-studied member of this family is CDC114, which is also known as ISGF2. ISGF2 is a transcription factor that is involved in the regulation of cell growth, differentiation, and inflammation. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

CDC113 is similar to ISGF2 in terms of its structure and function. It consists of a domain that is similar to ISGF2, which is composed of a nucleotide-binding oligomerization domain (NBD) and a coiled-coil domain. The NBD is responsible for binding to DNA and the coiled-coil domain is responsible for the protein's stability and functions as a dimer.

CDC113 is also similar to ISGF2 in its ability to interact with other proteins. It has been shown to interact with several proteins, including the transcription factor NF-kappa-B. This interaction between CDC113 and NF-kappa-B suggests that it may be involved in the regulation of cellular processes, such as cell growth, differentiation, and inflammation.

CDC113 is also unique in that it is expressed in various tissues and cell types. This makes it a potential biomarker for the diagnosis and treatment of diseases. For example, high levels of CDC113 have been shown to be associated with the development of certain types of cancer. Additionally, the protein has also been shown to be involved in the regulation of inflammation, which makes it a potential target for drugs that are used to treat inflammatory disorders.

CDC113 as a drug target

CDC113 has the potential to be a drug target for a variety of diseases. Its involvement in the regulation of cell growth, differentiation, and inflammation makes it a potential target for drugs that are used to treat these disorders.

One of the main potential drug targets for CDC113 is the treatment of cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. The regulation of cell growth and differentiation is critical for the development and progression of cancer. CDC113 is involved in these processes, which makes it a potential target for drugs that are used to treat cancer.

Another potential drug target for CDC113 is the treatment of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells. The regulation of cell growth and differentiation is important for the development and progression of these diseases. CDC113 is involved in these processes, which makes it a potential target for drugs that are used to treat neurodegenerative diseases.

CDC113 is also a potential target for the treatment of autoimmune disorders. Autoimmune disorders are characterized by the immune system attacking the body's own tissues. These disorders can cause a range of symptoms, including inflammation, autoimmune diseases, and fatigue. The regulation of cell growth and differentiation is

Protein Name: Coiled-coil Domain Containing 113

Functions: Component of centriolar satellites contributing to primary cilium formation

The "CCDC113 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC113 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets